

SIERRA LEONE Support for Injection Safety Devices

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sierra Leone										
2. Grant number: 17-SLE-32a-X										
3. Date of Decision Letter: 13 June 2017										
4. Date of the Partnership Framework Agreement: 10 March 2013										
5. Programme title: Injection Safety Devices ¹										
6. Programme duration²: 2017										
7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)										
<table border="1" style="margin: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 30%;">2017</th> <th style="width: 30%;">Total³</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">Programme Budget (US\$)</td> <td style="text-align: center;">102,500</td> <td style="text-align: center;">102,500</td> </tr> </tbody> </table>		2017	Total ³	Programme Budget (US\$)	102,500	102,500				
	2017	Total ³								
Programme Budget (US\$)	102,500	102,500								
8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴										
<table border="1" style="margin: auto; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;">TOTAL Injection Safety Devices to be purchased with Gavi funds in each year</th> <th style="width: 30%;">2017</th> </tr> </thead> <tbody> <tr> <td>Number of AD syringes</td> <td style="text-align: center;">1,942,400</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td style="text-align: center;">88,300</td> </tr> <tr> <td>Number of safety boxes</td> <td style="text-align: center;">22,400</td> </tr> <tr> <td>Annual Amounts for Injection Safety Devices for all Gavi vaccines (US\$)</td> <td style="text-align: center;">102,500</td> </tr> </tbody> </table>	TOTAL Injection Safety Devices to be purchased with Gavi funds in each year	2017	Number of AD syringes	1,942,400	Number of re-constitution syringes	88,300	Number of safety boxes	22,400	Annual Amounts for Injection Safety Devices for all Gavi vaccines (US\$)	102,500
TOTAL Injection Safety Devices to be purchased with Gavi funds in each year	2017									
Number of AD syringes	1,942,400									
Number of re-constitution syringes	88,300									
Number of safety boxes	22,400									
Annual Amounts for Injection Safety Devices for all Gavi vaccines (US\$)	102,500									

¹ This does not include vaccines.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the amount that Gavi has approved.

Injection Safety Devices to be purchased with Gavi funds in each year, by type of support

New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose(s) per vial LIQUID,Routine	2017
Number of AD syringes	702,500
Number of re-constitution syringes	
Number of safety boxes	7,750
Annual Amounts for Injection Safety Devices for Vaccine (US\$)	35,500
New Vaccine Support (NVS), DTP-HepB-Hib, 10 dose(s) per vial, LIQUID,Routine	2017
Number of AD syringes	362,100
Number of re-constitution syringes	
Number of safety boxes	4,000
Annual Amounts for Injection Safety Devices for Vaccine (US\$)	18,500
New Vaccine Support (NVS), Yellow Fever, 10 dose(s) per vial, LYOPHILISED,Routine	2017
Number of AD syringes	303,800
Number of re-constitution syringes	32,500
Number of safety boxes	3,700
Annual Amounts for Injection Safety Devices for Vaccine (US\$)	17,000
New Vaccine Support (NVS), Measles, 10 dose(s) per vial, LYOPHILISED,SD Routine - Strat 1	2017
Number of AD syringes	458,100
Number of re-constitution syringes	55,800
Number of safety boxes	5,675

	Annual Amounts for Injection Safety Devices for Vaccine (US\$)	25,500	
	New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID,Routine	2017	
	Number of AD syringes	115,900	
	Number of re-constitution syringes		
	Number of safety boxes	1,275	
	Annual Amounts for Injection Safety Devices for Vaccine (US\$)	6,000	
<p>9. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.</p>			
<p>10. Self-procurement: Not applicable</p>			
<p>11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter.</p>			

On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes

13 June 2017